Skip to main content
OpenTrials

Clinical trial condition

Endometrial Mucinous Adenocarcinoma

Explore clinical trials studying Endometrial Mucinous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

7 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Endometrial Mucinous Adenocarcinoma trial results

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 137 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01642082

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, +6 more
Locations
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • Beebe Medical Center Lewes, Delaware, United States
  • Christiana Care Health System-Christiana Hospital Newark, Delaware, United States
  • Florida Hospital Orlando Orlando, Florida, United States
View all 30 locations
View Trial Details
Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00888173

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, +6 more
Locations
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Saint Vincent Hospital and Health Care Center Indianapolis, Indiana, United States
View all 35 locations
View Trial Details
Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01225887

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, +6 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Memorial University Medical Center Savannah, Georgia, United States
View all 59 locations
View Trial Details

Related conditions